Which Is The Best Investment For You? High Yield Pfizer or Higher Growth Merck? | FAST Graphs

Sdílet
Vložit
  • čas přidán 6. 06. 2024
  • Which is the best investment for you!
    If you are interested in investing in a high quality large pharmaceutical company, two of your primary choices would be Pfizer (PFE) or Merck (MRK), of course, Merck being the largest. Which one of these investments would suit you better as an investor?
    In this video, Chuck Carnevale, Co-founder of FAST Graphs, a.k.a. Mr. Valuation is going to answer that question - it depends on what your goals, objectives and risk tolerances are.
    Time Codes:
    0:00 - Introduction by Chuck Carnevale
    0:48 - Pfizer (PFE)
    10:10 - Merck & Co (MRK)
    Introducing The FAST Graphs’ Affiliate Program! Earn money and help other investors by introducing them to the most powerful fundamental analyzer software tool available. Help others become smarter and more profitable investors.
    fastgraphs.com/fast-graphs-af...
    Disclaimer: FAST Graphs is a tool designed to reveal and present information related to financial data and investment metrics. It is not intended to provide specific advice or recommendations. Instead, it offers a comprehensive view of relevant data, empowering users to make informed decisions based on their own analysis. It's your first step to a more comprehensive research and due diligence process. In short, it is a tool to think with. The opinions in this video are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned.
    Sign up for your 7-day free trial:
    www.fastgraphs.com
    SUBSCRIBE To Our CZcams Channel
    #investing #merck #pfizer

Komentáře • 68

  • @aritraray3068
    @aritraray3068 Před 21 dnem +22

    An update on Bristol Myers would be great. Thanks.

  • @100Mario81
    @100Mario81 Před 20 dny +10

    I got in on PFE at 30 by selling puts so my cost basis is 27 and selling calls on it to lower it. I would like to see a video on BMY if possible, thank you.

  • @MarshaBonForte
    @MarshaBonForte Před 21 dnem +10

    Great presentation as always. I bought Pfizer at $25 and change so I’m already up. It seemed like a no brainer. It is still a good buy.

  • @XbhSrs
    @XbhSrs Před 5 dny +60

    *Excellent! I really do have a question. For someone with less than $17,000 to trade or above. How would you recommend we enter into trading as a newbie? I am looking at trading with professional trader and copying their strategies rather than trading myself. I would greatly appreciate any suggestions*

    • @Michael68689
      @Michael68689 Před 5 dny +1

      I would suggest to reach out to Mavis. What impresses me most about Mavis is how well she accumulate profit for client's and explains basic concept of winning before actually trading for you. And letting you use her trade signals. And she will also teach you how to trade as she trade for you, and let you know when to enter and exit trade for maximum profit as she trade for you. This goes a long way to ensure winning trades.

    • @XbhSrs
      @XbhSrs Před 5 dny +1

      Please I'm a beginner, where can someone willing to start up trading reach Mavis?

    • @Michael68689
      @Michael68689 Před 5 dny +1

      She's mostly attend to client's faster on Telegrams, using the user name.

    • @Michael68689
      @Michael68689 Před 5 dny +2

      *Mavis131大大大 ...that's it*

    • @Anastasia349
      @Anastasia349 Před 5 dny +3

      I'm shocked that Mavis name was mentioned and recommended. I learn and earn through her analysis. Which I always speaks volumes about her and also recommend people to her

  • @menlubruce580
    @menlubruce580 Před 20 dny +6

    thanks Chuck, I too would like an update on BMY as well.

  • @topinvest4385
    @topinvest4385 Před 11 dny +3

    What is about Bristol-Myers Squibb? Can you maybe give us an Update?
    Greetings from Germany :)

  • @iangantner6976
    @iangantner6976 Před 20 dny +5

    Thumbs up. Recently started acquiring Pfizer. Not sure what makes me more excited- Pfizer having spent quite a bit on cancer related acquisitions or the potential yield on cost increases. Either way, I feel like it’s a win. If any of my dollars help cancer patients, I’m happy. If I make money I’m happy.. win/win!

  • @wmartin
    @wmartin Před 21 dnem +7

    Thanks Chuck!

  • @photomanual01
    @photomanual01 Před 21 dnem +3

    Great stuff as always! Any thoughts on Whirlpool? I enjoyed your video years ago, "let's take it for a whirl" if memory serves...

  • @Felcity
    @Felcity Před 20 dny +2

    Thank you very very much for this kind of content - for free!

  • @kevinmendoza4402
    @kevinmendoza4402 Před 21 dnem +5

    I’m buying both! 🚀🤑💎👐

  • @janoz06
    @janoz06 Před 21 dnem +1

    Excellent video thanks

  • @hahaman5255
    @hahaman5255 Před 18 dny +2

    Can you do Bmy analysis sir?

  • @_VlCTOR_
    @_VlCTOR_ Před 20 dny +4

    what is the problem with BMY?

    • @FASTgraphs
      @FASTgraphs  Před 20 dny +5

      Patent cliff with new blockbuster drugs coming slowly. Dividend appears safe. Long term play requiring patience. www.bms.com/assets/bms/us/en-us/pdf/investor-info/boa-global-healthcare-conference-20224-transcript.pdf

  • @rolf5282
    @rolf5282 Před 20 dny +1

    Yes as always great information thank's from europe

  • @martinithechobit
    @martinithechobit Před 15 dny

    Ty boss as my experience in the pharmacy these are big names. But handful of big boys out there as well.

  • @dieterfrommunich758
    @dieterfrommunich758 Před 6 dny

    thank you

  • @marcojansen9599
    @marcojansen9599 Před 19 dny +1

    With Pharma it is always difficult to convert pipeline to future (3-8 years) growth numbers for outsiders.

    • @FASTgraphs
      @FASTgraphs  Před 19 dny +1

      I start by looking at the projections of the leading analysts following the stock. In addition to their own work they also are given guidance by the companies themselves. Furthermore, this is where the analyst scorecard comes in. Regards, Chuck

  • @donkemp8151
    @donkemp8151 Před 13 dny

    Bought Merck at $82. I think I’ll hold for a bit longer.

  • @user-vm6ck7lt6v
    @user-vm6ck7lt6v Před 21 dnem +1

    Is CHWY a good growth stock?

  • @felipelorenzodellalucia1245

    Hi Chuck, how come a negative growth stock should be valued at a 15 PE and a 2% positive growth valued as 13 PE? It doesn't make sense. Shouldn't the negative growth be somewhat truncated at the 13 PE?

    • @FASTgraphs
      @FASTgraphs  Před 19 dny +2

      Because valuation is only part of the equation and represents soundness. Rate of return is a function of the future growth or lack thereof. In other words the negative grower is a bad investment in any valuation. To repeat, valuation is a measurement of soundness not rate of return. Here is an article I wrote discussing it in more detail: fastgraphs.com/blog/valuation-is-a-measurement-of-soundness-and-not-the-primary-total-return-producer-part-1/ regards, Chuck

    • @felipelorenzodellalucia1245
      @felipelorenzodellalucia1245 Před 19 dny

      Thanks for the clarification, Chuck!

  • @Gee60711
    @Gee60711 Před 20 dny

    I sold both and increased my investment in the S&P 500. ETFs are the best way to achieve peace of mind to a certain extent.

    • @FASTgraphs
      @FASTgraphs  Před 19 dny +2

      The S&P 500 is at an all-time high. Furthermore, it is a market of stocks and not a stock market which implies that their overvalued undervalued and fairly valued stocks within the index. Common sense should indicate that buying attractively valued stocks would outperform the S&P 500 over the long run when the S&P 500 is this overvalued. In short this is the worst time to be investing in the index. The cardinal rule of investing is buy low and sell high not the other way around. Just trying to be helpful. Chuck

    • @ahsugoi
      @ahsugoi Před 19 dny

      ​@@FASTgraphshave you considered that the S&P may be at an all time high because of a substantial increase in the money supply? You've been saying this for what seems like a while now. It may be a new normal that you need to adjust to rather than clinging to an old valuation framework.

    • @FASTgraphs
      @FASTgraphs  Před 19 dny +1

      @@ahsugoi this is been the longest bull market in history and all bull markets end with a bear market. And valuation is always relevant and cannot go out of date the principles of business, economics, and accounting are timeless. Valuation matters and it matters a lot. And all that macroeconomic nonsense is just that macroeconomic nonsense. Price is what you pay and value is what you get. I was trying to be helpful but go ahead continue to be a genius in a bull market. Regards, Chuck

    • @ahsugoi
      @ahsugoi Před 19 dny +1

      @@FASTgraphs there will no doubt be another bear market. I'm just offering another take on what you continually insist is persistent overvaluation. If there's a lot more money in circulation, what do you think that will do to asset prices? Valuation is relative. If everything (the market and other assets) is overvalued, is it overvaluation or might it be repricing due to an increase in the money supply?

    • @FASTgraphs
      @FASTgraphs  Před 19 dny

      @@ahsugoi Do you understand earning yield?

  • @bonanzatime
    @bonanzatime Před 12 dny

    I'm all in with the rapper, Merky Merk Merk😎

  • @kelleyhaldorson209
    @kelleyhaldorson209 Před 17 dny

    I have decided to ETF my pharmaceuticals. I can't follow the pipeline info, it is out of my realm of competence by far!

  • @davebean2886
    @davebean2886 Před 21 dnem +7

    Comparison to BMY which was looked at a year ago?
    czcams.com/video/9RQr_IWIs1g/video.html

  • @Buffetology
    @Buffetology Před 20 dny +3

    Can you please stop giving away the secret sauce ! Wish I found you decades earlier

  • @pearlperlitavenegas2023
    @pearlperlitavenegas2023 Před 21 dnem +3

    2nd!

  • @JakeandAnnie
    @JakeandAnnie Před 21 dnem

    What about Pfizer's spin off Viatris?

    • @FASTgraphs
      @FASTgraphs  Před 21 dnem

      what about Mercks spinn-off Organon. My point is that they are separate companies not relevant to this video.

  • @lolman456
    @lolman456 Před 21 dnem +3

    1st

  • @Prachka1
    @Prachka1 Před 21 dnem +3

    Any pharmaceutical company that profits from not developing actual cures and only develops dependency drugs - deserves $0 of my dollars and that is what they are getting.

    • @derf2170
      @derf2170 Před 21 dnem +9

      Until you get sick and need medicine

    • @Prachka1
      @Prachka1 Před 21 dnem

      @@derf2170 read above post

    • @Prachka1
      @Prachka1 Před 21 dnem

      @@derf2170 read above comment

    • @Prachka1
      @Prachka1 Před 21 dnem

      @@derf2170 , again - read, key word here, above comment.

    • @Prachka1
      @Prachka1 Před 21 dnem

      @@derf2170 medicine - not drug.

  • @mmm-cake
    @mmm-cake Před 19 dny +1

    Thanks Chuck!